Company profile for Inhibrx

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Inhibrx is a clinical stage biologic immunotherapeutic company focused on the treatment of high unmet medical needs in oncology, infectious disease and inflammatory conditions. Inhibrx’s proprietary platforms enable fit-for-function biotherapeutics that optimally interface with the biology of each target antigen to focus and conditionally modulate immune activities and mediate enhanced signaling. Therapeutic proteins include...
Inhibrx is a clinical stage biologic immunotherapeutic company focused on the treatment of high unmet medical needs in oncology, infectious disease and inflammatory conditions. Inhibrx’s proprietary platforms enable fit-for-function biotherapeutics that optimally interface with the biology of each target antigen to focus and conditionally modulate immune activities and mediate enhanced signaling. Therapeutic proteins include multispecific and multivalent molecules designed and crafted using our composite modular single domain antibody technology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Torrey Pines Science Park 11025 N Torrey Pines Rd #200 La Jolla, CA 92037
Telephone
Telephone
(858) 795-4220
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/inhibrx-reports-third-quarter-2025-financial-results-302615156.html

PR NEWSWIRE
14 Nov 2025

https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-conferences-302604643.html

PR NEWSWIRE
05 Nov 2025

https://www.prnewswire.com/news-releases/inhibrx-biosciences-reports-positive-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-provides-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion-cohorts-302593250.html

PR NEWSWIRE
24 Oct 2025

https://www.fiercebiotech.com/biotech/inhibrx-intends-fda-submission-after-antibody-scores-ph-2-win-rare-bone-cancer

FIERCE BIOTECH
24 Oct 2025

https://www.prnewswire.com/news-releases/inhibrx-to-host-webcast-presentation-of-topline-results-from-its-registrational-trial-of-ozekibart-inbrx-109-in-chondrosarcoma-and-to-provide-updates-on-colorectal-cancer-and-ewing-sarcoma-expansion-cohorts-302591875.html

PR NEWSWIRE
23 Oct 2025

https://www.fiercebiotech.com/biotech/sanofis-17b-rare-disease-bet-beats-csls-zemaira-phase-2-face

FIERCE BIOTECH
22 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty